Silver Book Fact

After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who received traditional chemotherapy.

Aspinall, M and R Hamermesh. Realizing the Promise of Personalized Medicine. Harvard Bus Rev. 2007; 85(10): 108-17. https://hbr.org/2007/10/realizing-the-promise-of-personalized-medicine

Reference

Title
Realizing the Promise of Personalized Medicine
Publication
Harvard Bus Rev
Publication Date
2007
Authors
Aspinall, M and R Hamermesh
Volume & Issue
Volume 85, Issue 10
Pages
108-17
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.  
  • Treating cancer patients with oral medicine versus intravenous chemotherapy results in a 2/3 reduction in hospital time and a greater than 50% reduction in costly medication side effects.  
  • Every additional dollar spent on overall breast cancer treatment has produced health gains valued at $4.80.  
  • In 1971, one in 69 people was a cancer survivor (three million survivors). In 2014, that number grew to one in 22 people (14.5 million survivors).  
  • For women age 40 or older, timely mammograms could reduce breast cancer mortality by about 16%–compared to those who are not screened.